International Cannabis Weekly: 12
Business & Investment
- Canadian producer, Aurora Cannabis, have made their first shipment to the German marketplace.
- The value of medical cannabis is expected to grow by 25%-35% compounded annually over the next 5 years.
- Research from Zelda Therapeutics shows positive results in the treatment of autism symptoms with medical cannabis.
- Cronos Group have announced a supply agreement with Cannamedical Pharma in Germany.
Regulations & Politics
- The Duke of Cambridge has entered the debate on whether tolegalise cannabis in Britain.
- Denmark will embark on trials for multiple sclerosis and three other types of patients in 2018.
- The tide is rapidly changing across Europe and here’s what you need to knowabout the legalisation for medical use.
- The Belgian Socialist Party has submitted a bill proposing a model for regulating cannabis.
The New Opium Act was implemented in the Netherlands in 1976, which was to lead the way for the so-called ‘Policy of Tolerance. Initially, the policy was meant as a first step towards full regulation on soft drugs – although here we are 40 years later with very little progress.
The European Cannabis Report
Trend No.3 – Shifting Consumer Perceptions
The story of medicinal cannabis has been gaining traction across Europe, helping to broaden perception and public opinion even in relatively conservative countries like Ireland.
Education, both to the public and the media, is required to ensure that the progress made in the medical field is not tarnished with lazy opinion or stereotype.
On the global cannabis industry
International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 70,000+ subscribers.